Cartesian Therapeutics, Inc. Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc.

RNAC

Clasificación en acciones #18395
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Precio por acción
$6.27
Última sincronización: 2026-10-16
Capitalización bursátil
$189.70M
Cambio (1 día)
-4.71%
Cambio (1 año)
839.61%
País
US
Comercio Cartesian Therapeutics, Inc. (RNAC)

Categoría

Healthcare
Historial de dividendos de Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (símbolo bursátil: RNAC) realizó un total de 0 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: 0.00
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Cartesian Therapeutics, Inc. (RNAC) desde 2026 hasta 2026
Pagos anuales de dividendos
Año Dividendo (ajustado por splits de acciones) Cambiar
Not enough data for the provided dates.
Lista de todos los pagos de dividendos
Año Dividendo Cambiar
Not enough data for the provided dates.
Pagos de dividendos de empresas similares o competidoras
Empresa Número de pagos de dividendos País
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL